Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx Pharmaceuticals Inc.

www.acelrx.com

Latest From AcelRx Pharmaceuticals Inc.

Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote

Risk committee has joined nearly all opioid reviews over past few years but didn’t for AcelRx's sublingual product; Raeford Brown, the analgesic advisory committee chair who was unable to attend the meeting, voices his displeasure with the vote. 
Advisory Committees Neurology

Dsuvia's Thumbs Up From US FDA Advisory Panel Is First Positive Vote For An Opioid In 2018

 AcelRx's sublingual opioid fills a need for narrow population, panelists conclude, despite US FDA's concerns about tablet size and committee's own worries about efficacy.
Advisory Committees Neurology

AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets

US FDA appears generally satisfied that AcelRx fulfilled initial safety concerns cited in October 2017 complete response letter.
Advisory Committees Neurology

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SuRx Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AcelRx Pharmaceuticals Inc.
  • Senior Management
  • Vincent J Angotti, CEO
    Raffi Asadorian, CFO
    Larry G Hamel, Chief Dev. Officer
    Pamela P Palmer, MD, PhD, CMO
    Mark A Evashenk, VP, Clinical Operations
    Kim Gaumer, VP, Reg. Affairs & Quality Assurance
  • Contact Info
  • AcelRx Pharmaceuticals Inc.
    Phone: (650) 216-3500
    351 Galveston Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register